As ImmusanT initiates the process to develop its treatment regimens for celiac disease and Type 1 diabetes, the company has fast-paced its hiring activity by bringing on board Ken Truitt M.D. Daiichi Sankyo’s SVP for internal medicine therapeutics as its new Chief Medical Officer.
Holland-based Genesis Innovation Group LLC raised $7.2 million of its $10 million goal toward a fund to invest in early-stage healthcare companies developing medical devices and orthopedic technologies.
Cambridge, Mass.-based Biotech startup Accent Therapeutics announced $40 million A series funding to develop cancer treatment based on epitranscriptomics, an RNA-modifying protein (RMPs) which have been connected to recent cancer studies.
iPhone maker Apple is all set to disrupt the conventionalities of medical data storage methodologies. The company has announced the development of a new health record app, a new standard that has been adopted by many big companies for transferring records across scattered systems. Apple is all set to break the traditional systems of several silos in which medical data is stored.
FMCG major Marico has announced that it will be investing in Revolutionary Fitness, owner of health and fitness app Revofit. The company stated that it will acquire around 22.5 percent stake in the health startup.
This year AbbVie launched Imbruvica, a single tablet for blood cancer treatment. It has been designed as a convenient therapy measure for patients who used the old tablets as often as four times a day. Adapting the new single tablet in their treatment regimens will prove to be an expensive proposition for some patients as the new tablet comes with a price tag of $400 each, triple the cost of the older tablets.
Prosecutors have already charged Insys founder John Kapoor and won guilty pleas from two characters in an ongoing kickbacks probe. Now, the Justice Department has escalated the case by joining in with whistleblowers who've detailed a stunning range of techniques the company allegedly used to push its powerful opioid painkiller.
Merck KGaA will hand P&G a consumer business that has grown 6% over the past two years. (Merck KGaA) Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.